Search - tctmd.com

Displaying 461 - 480 of 916

Sort: Relevancy | Date

Presentation

Mortality Following Nonemergent, Uncomplicated TLR After PCI

April 20, 2018

Presentation Fellows 2018

Complete Revascularization of Complex Higher Risk (and Indicated) Patients: The Rationale

Presenter: Gary S. Mintz, Jeffrey W. Moses

April 14, 2018

Presentation CIT 2018

Best Practice for PCI: Lessons from SYNTAX II

Presenter: Patrick W. Serruys

March 23, 2018

Presentation ACC 2018

A Phase II Randomized Double-Blind, Placebo Controlled Study in Patients with Critical Limb Ischemia to Evaluate the Safety and Efficacy of hSDF-1 plasmid (JVS-100) Post Open or Endovascular Revascularization (STOP-PAD Trial)

Presenter: Mehdi H. Shishehbor

March 12, 2018

Presentation CHIP at ACC 2018

Opening Salvo: Where PCI Needs to Go in the Next 5-10 Years

Presenter: Martin B. Leon

March 09, 2018

Presentation JIM 2018

Left Ventricular Support During Complex Transradial Percutaneous Coronary Intervention for Complete Revascularization

Presenter: Carlo Briguori

February 23, 2018

Presentation

Complete vs Culprit-Only Revascularization in STEMI With Multivessel Disease

February 15, 2018

Presentation TTT 2018

Should we revascularized CTO lesions? Decision CTO vs Euro CTO trial

Presenter: Alfredo R. Galassi

January 14, 2018

Presentation Controversies and Advances 2017

FFR is the Gold Standard For Revascularization Decision Making

Presenter: Matthew J. Price

November 17, 2017

Presentation Controversies and Advances 2017

FFR is NOT the Gold Standard for Revascularization Decision Making

Presenter: Paul S. Teirstein

November 17, 2017

Presentation TCT 2017

TAVR in AS Patients With Stable Coronary Disease: Evolving Treatment Issues (When to Consider CABG, Timing of PCI, and Completeness of Revascularization)

Presenter: Torsten P. Vahl

November 01, 2017

Presentation TCT 2017

Case #2 Conclusion: A Symptomatic Diabetic Patient With Chronic Kidney Disease and 3-Vessel Disease How We Treated

Presenter: David J. Maron, Alan C. Yeung, Vasim Farooq

November 01, 2017

Presentation TCT 2017

Case #3 Introduction: A Symptomatic Diabetic Patient With Chronic Kidney Disease and 3-Vessel Disease How Should We Treat?

Presenter: David J. Maron, Alan C. Yeung, Vasim Farooq

November 01, 2017

Presentation TCT 2017

Case #2 Introduction: An Asymptomatic Diabetic Patient With Normal Exercise Tolerance and Multivessel Disease How Should We Treat?

Presenter: David J. Maron, Alan C. Yeung, Frederick Feit

November 01, 2017

Presentation TCT 2017

Case #1 Conclusion: A Diabetic Patient With Left Main Disease How We Treated

Presenter: David J. Maron, Alan C. Yeung, Jung-Min Ahn

November 01, 2017

Presentation TCT 2017

Case #1 Introduction: A Diabetic Patient With Left Main Disease How Should We Treat?

Presenter: David J. Maron, Alan C. Yeung, Jung-Min Ahn

November 01, 2017

Presentation TCT 2017

Should Pre-Diabetes Affect Revascularization Decisions?

Presenter: David J. Maron, Alan C. Yeung, Clemens von Birgelen

November 01, 2017

Presentation TCT 2017

Current State-of-the-Art Diabetes Medical Management and Novel Therapies in Clinical Trials

Presenter: David J. Maron, Alan C. Yeung, Michael E. Farkouh

November 01, 2017

Presentation TCT 2017

When Is Medical Therapy the Best Choice in the Diabetic Patient?

Presenter: David J. Maron, Alan C. Yeung

November 01, 2017

Presentation TCT 2017

Is There a Preferred Stent for the Diabetic Patient?

Presenter: David J. Maron, Alan C. Yeung, Upendra Kaul

November 01, 2017

Advertisement

Mortality Following Nonemergent, Uncomplicated TLR After PCI

Complete Revascularization of Complex Higher Risk (and Indicated) Patients: The Rationale

Best Practice for PCI: Lessons from SYNTAX II

A Phase II Randomized Double-Blind, Placebo Controlled Study in Patients with Critical Limb Ischemia to Evaluate the Safety and Efficacy of hSDF-1 plasmid (JVS-100) Post Open or Endovascular Revascularization (STOP-PAD Trial)

Opening Salvo: Where PCI Needs to Go in the Next 5-10 Years

Left Ventricular Support During Complex Transradial Percutaneous Coronary Intervention for Complete Revascularization

Complete vs Culprit-Only Revascularization in STEMI With Multivessel Disease

Should we revascularized CTO lesions? Decision CTO vs Euro CTO trial

FFR is the Gold Standard For Revascularization Decision Making

FFR is NOT the Gold Standard for Revascularization Decision Making

TAVR in AS Patients With Stable Coronary Disease: Evolving Treatment Issues (When to Consider CABG, Timing of PCI, and Completeness of Revascularization)

Case #2 Conclusion: A Symptomatic Diabetic Patient With Chronic Kidney Disease and 3-Vessel Disease How We Treated

Case #3 Introduction: A Symptomatic Diabetic Patient With Chronic Kidney Disease and 3-Vessel Disease How Should We Treat?

Case #2 Introduction: An Asymptomatic Diabetic Patient With Normal Exercise Tolerance and Multivessel Disease How Should We Treat?

Case #1 Conclusion: A Diabetic Patient With Left Main Disease How We Treated

Case #1 Introduction: A Diabetic Patient With Left Main Disease How Should We Treat?

Should Pre-Diabetes Affect Revascularization Decisions?

Current State-of-the-Art Diabetes Medical Management and Novel Therapies in Clinical Trials

When Is Medical Therapy the Best Choice in the Diabetic Patient?

Is There a Preferred Stent for the Diabetic Patient?

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content